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O steoarthritis (OA) is the most common type of arthritis, andthe knee is the most common site of symptomatic OA.1
Knee OA is responsible for a higher incidence of disability than
any other long-term conditions.2 Topical therapies present a
therapeutic option for OA pain management. Nonsteroidal anti-
inflammatory drugs (NSAIDs), salicylates, and capsaicin are cur-
rently the main topical therapies available.3 There is a need for
safe and effective drugs for patients who do not respond well
to conventional medical therapy. Indeed, such patients are turn-
ing increasingly to complementary/alternative medicines.4,5
One of the traditional methods for management of knee
pain in some rural area of Iran is application of topical olive oil,
as reported by Avicenna6 in his 10th-century book Canon of
Medicine. Although the composition of olive oil is complex, the
major groups of compounds thought to contribute to its observed
health benefits include oleic acid, phenolics, and squalene,7 all
of which have been reported to inhibit oxidative stress.8 Re-
searchers reported beneficial effects of olive oil on rheumatoid
arthritis after oral consumption.9 In 2005, (j)-oleocanthal, the
dialdehydic form of (j)-deacetoxy-ligstroside aglycone pres-
ent in freshly pressed extra virgin olive oil, was shown to have
properties of an NSAID.10
Although topical virgin olive oil is traditionally used in Iran
in treating knee pain as an herbal medication, our survey did
not find any scientific evaluation of its efficacy. Accordingly, we
conducted a pilot prospective, comparative, randomized, double-
blinded trial of topical virgin olive oil therapy versus piroxicam
gel in the treatment of knee OA. The report was prepared as
recommended by the CONSORT statement11,12 and its elabora-
tion on herbal interventions.13
MATERIALS AND METHODS
Trial Design
This was a 4-week, balanced randomization (1:1), double-
blind, standard controlled, parallel-group, phase 2 pilot trial
conducted in Ardabil, Iran. After enrollment, eligible patients
underwent 1-week (or at least 5 half-lives, whichever was longer)
washout of analgesics before being randomized to receive pir-
oxicam or olive oil daily for 4 weeks. After a baseline visit,
patients returned to outpatient clinic on weeks 1, 2, 3 and 4 for
assessment of efficacy, safety, and compliance. The study was
approved by the university ethical board as well as consistency
with principles of the Declaration of Helsinki. All the patients
gave a written informed consent. The study was also registered
with ClinicalTrials.gov (identifier NCT00670475).
Changes to Trial Design
Although the trial was approved to include both sexes, the
low recruitment rate of male patients skewed the study, and it
was changed to only female sex. Initially, the study design was
on 100 patients on each arm, but based on accumulating data
from participants’ outcomes, which were monitored by an in-
dependent body without breaking the blindness, and unexpected
long duration of study that led to financial limitation, a recom-
mendation was applied to reduce the sample size to 30 patients
on each arm.
Settings and Participants
The study took place at the rheumatology clinic of Imam
Hospital, Ardabil University of Medical Sciences, Ardabil, Iran,
from April 2008 to April 2010. Participants were eligible if they
were female adults aged between 40 and 85 years with a di-
agnosis of OA of 1 or both knees according to the American
College of Rheumatology criteria and a flare of pain after with-
drawal of prior therapy with either an oral NSAID or acet-
aminophen (used at least 3 d/wk during the previous month).
Key requirement for randomization at the baseline visit was a
Western Ontario and McMaster Universities Osteoarthritis In-
dex (WOMAC) pain subscale score of 9 or higher on a 20-point
scale.14 Pain was scored at the screening visit, after which prior
therapy was withdrawn. The patient scored the pain again at the
baseline visit. A flare was defined as an increase in total pain
subscale score of at least 2 during the screening and baseline
visits.
Patients were excluded from the study if they had second-
ary arthritis related to systemic inflammatory arthritis; cortico-
steroid use, ongoing use of prohibited medication including
NSAID, other oral analgesic, muscle relaxant, or low-dose an-
tidepressant for any long-term pain management; ongoing use of
glucosamine or chondroitin, a sensitivity to NSAIDs, acetamin-
ophen, dimethyl sulfoxide, propylene glycol, glycerine, or eth-
anol; clinically active renal, hepatic, or peptic ulcer disease,
history of alcohol, or drug abuse; lactation; concomitant skin
disease at the application site; and current application for dis-
ability benefits on the basis of knee OA, fibromyalgia, other
painful, or disabling condition affecting the knee.
Randomization and Interventions
After the washout period, eligible patients randomized in
1:1 ratio to receive piroxicam or virgin olive oil. The gel of
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